The prevalence of asthma differs between men and women, and furthermore, the difference changes over the lifespan. “Asthma is ...
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Cvrx, Spinal Resources.
The FDA’s Center for Devices and Radiological Health posted two important guidances just in the first week of the new year. The agency seems determined to sustain that pace with a new draft guidance ...
Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of ...
Hyperactivity of the transmembrane adaptor protein STING, which normally helps the cell respond to infection and injury, has been implicated in several autoimmune or inflammatory diseases, including ...
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common pediatric cancer. Although pediatric ALL is cured in over 90% of cases, children with high-risk BCP-ALL present increased ...
Prenaital ApS has filed a patent for technology that may identify risks of spontaneous pre-term birth. Spontaneous preterm birth (sPTB) is usually defined as birth occurring before 37 weeks of ...
It’s official. A year after President Donald Trump issued an order requiring the U.S. to withdraw from the World Health Organization (WHO), that withdrawal has been completed.
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the ...
Alveus Therapeutics Inc. has obtained IND clearance from the FDA for ALV-100, for chronic weight management, enabling initiation of a phase Ib study. Dosing has now commenced in the study.
Citing the “totality of data,” Sanofi SA plans to file global regulatory submissions this year for amlitelimab in atopic ...
Recent evidence has suggested threonine tyrosine kinase (TTK) as a crucial element of the mitotic checkpoint for the correct ...